CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
OPERATING ACTIVITIES:
Net income (loss)	$ (272,107)	$ 28,690	$ (547)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	55,594	55,115	55,340
Deferred income tax expense (benefit)	(87,242)	30,690	(305)
Share-based compensation	9,027	9,896	7,719
Asset impairment charges	375,381	24,960	88,084
Loss on sale/disposal of assets	1,559	848	290
Loss (gain) on investment securities		(3,313)	(2,914)
Loss on extinguishment of debt	448
Loss on sale of intangible asset		15,514
Amortization of debt discount and other debt issuance costs	17,641	21,866	20,577
Other noncash expenses	2,579	5	1,889
Changes in assets and liabilities which provided (used) cash, net of acquisitions:
Accounts receivable, net	84,949	(48,585)	1,701
Inventories	(2,336)	(19,031)	(7,700)
Prepaid income taxes/Income taxes payable	18,319	2,174	(17,748)
Other assets	2,643	(2,287)	1,916
Rebates payable	(3,225)	4,807	14,369
Royalties payable	10,260	2,940	(2,112)
Restructuring liability	(4,391)	1,275	1,301
Settlement liability			1,000
Accounts payable	(43,274)	(4,953)	5,000
Accrued expenses	(1,620)	(5,074)	3,252
Accrued payroll and payroll-related expenses	12,105	2,986	(5,739)
Net cash provided by operating activities	176,310	118,523	165,373
INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(24,340)	(52,316)	(48,694)
Proceeds from sale of property, plant and equipment	14,450	28	112
Proceeds from sale of outstanding loan to Variable Interest Entity ("VIE")	5,600
Advance to VIE		(10,254)
Purchases of intangible asset	(3,000)	(19,038)
Proceeds from sale of investment securities		94,047	67,828
Purchase of investment securities		(63,643)	(77,911)
Net cash used in investing activities	(7,290)	(51,176)	(58,665)
FINANCING ACTIVITIES:
Repayments of short-term borrowings and long-term debt	(126,743)	(85,705)	(178,233)
Purchase of noncontrolling interest			(1,500)
Acquisition-related contingent consideration			(35,000)
Proceeds from issuance of stock	1,180	4,142	2,818
Payment of debt issuance costs	(1,102)
Purchase of treasury stock	(592)	(4,642)	(1,898)
Net cash used in financing activities	(127,257)	(86,205)	(213,813)
Effect on cash and cash equivalents of changes in foreign exchange rates	(100)	(293)	73
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	41,663	(19,151)	(107,032)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	98,586	117,737	224,769
CASH AND CASH EQUIVALENTS, END OF PERIOD	140,249	98,586	117,737
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid (net of amounts capitalized of $00, $1.6 million and $1.3 million for the years ended June 30, 2019, 2018 and 2017, respectively)	66,750	63,563	67,115
Income taxes paid (refunded)	(4,641)	(6,559)	19,150
Credits issued pursuant to a Settlement Agreement		17,000	5,000
Andor Pharmaceuticals, LLC ("Andor") License Agreement acquisition	16,000
Accrued purchases of property, plant and equipment	$ 765	$ 3,572	$ 446